<DOC>
	<DOCNO>NCT00821535</DOCNO>
	<brief_summary>To confirm safety pharmacokinetics maraviroc follow single oral dose 300 mg maraviroc healthy male Japanese volunteer .</brief_summary>
	<brief_title>Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male Japanese subject age 21 50 year inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Positive result HIV , Hepatitis B surface antigen ( HbsAg ) HCV antibody . Hypersensitivity/allergic reaction component maraviroc , include soy lecithin .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>pharmacokinetics , Japanese , healthy volunteer , maraviroc</keyword>
</DOC>